Identification

Name
Temocapril
Accession Number
DB08836
Type
Small Molecule
Groups
Experimental, Investigational
Description

Temocapril is a prodrug-type angiotensin-I converting enzyme (ACE) inhibitor not approved for use in the United States, but is approved in Japan and South Korea. Temocapril can also be used in hemodialysis patients without risk of serious accumulation.

Structure
Thumb
Synonyms
  • Temocaprilum
External IDs
CS-622
Product Ingredients
IngredientUNIICASInChI Key
Temocapril hydrochloride8G820I95VP110221-44-8XDDQNOKKZKHBIX-ASBZXGSUSA-N
International/Other Brands
Acecol (Sankyo)
Categories
UNII
18IZ008EU6
CAS number
111902-57-9
Weight
Average: 476.609
Monoisotopic: 476.143963396
Chemical Formula
C23H28N2O5S2
InChI Key
FIQOFIRCTOWDOW-BJLQDIEVSA-N
InChI
InChI=1S/C23H28N2O5S2/c1-2-30-23(29)17(11-10-16-7-4-3-5-8-16)24-18-15-32-20(19-9-6-12-31-19)13-25(22(18)28)14-21(26)27/h3-9,12,17-18,20,24H,2,10-11,13-15H2,1H3,(H,26,27)/t17-,18-,20-/m0/s1
IUPAC Name
2-[(2S,6R)-6-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-5-oxo-2-(thiophen-2-yl)-1,4-thiazepan-4-yl]acetic acid
SMILES
CCOC(=O)[[email protected]](CCC1=CC=CC=C1)N[[email protected]]1CS[[email protected]@H](CN(CC(O)=O)C1=O)C1=CC=CS1

Pharmacology

Indication

Temocapril is an ACE inhibitor primarily indicated in the treatment of hypertension and congestive heart failure, diabetic nephropathy, and improvement of prognosis for coronary artery diseases (including acute myocardial infarction).

Structured Indications
Not Available
Pharmacodynamics

Temocapril is a prodrug of its active metabolite (and diacid form) temocaprilat which contains a thiazepine ring. Temocaprilat has slightly higher potency than enalaprilat in ACE inhibition isolated from rabbit lung. ACE inhibitors exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility.). When compared with other Angiotensin-converting Enzyme Inhibitors, temocapril's advantages include a rapid onset of action and what research suggests is tighter vascular ACE binding than enalaprilat.

Mechanism of action
TargetActionsOrganism
UAngiotensin-converting enzyme
inhibitor
Human
Absorption

Temocapril is rapidly absorbed in the gastrointestinal tract and converted into the diacid (active) metabolite, which inhibits ACE in plasma.

Volume of distribution
Not Available
Protein binding

99.5%, including those with renal impairment.

Metabolism
Not Available
Route of elimination

Temocapril is eliminated primarily through the liver and kidneys.

Half life

13.1 hours in patients with normal liver function.

Clearance

19.4% urinary recovery.

Toxicity

In rats, whether or male or female, the LD50 values of temocapril were higher than 5000 mg/kg.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Temocapril Metabolism PathwayDrug metabolism
Temocapril Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Temocapril.Investigational
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Temocapril.Experimental
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Temocapril.Approved, Investigational
AcebutololAcebutolol may increase the hypotensive activities of Temocapril.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Temocapril.Approved, Investigational
AcemetacinThe therapeutic efficacy of Temocapril can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
Acetylsalicylic acidThe therapeutic efficacy of Temocapril can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Temocapril.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Temocapril.Approved, Withdrawn
AlfuzosinAlfuzosin may increase the hypotensive activities of Temocapril.Approved, Investigational
AliskirenAliskiren may increase the hypotensive, nephrotoxic, and hyperkalemic activities of Temocapril.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Temocapril.Approved
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Temocapril.Experimental
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Temocapril.Approved
AloxiprinThe therapeutic efficacy of Temocapril can be decreased when used in combination with Aloxiprin.Experimental
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Temocapril.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Temocapril.Approved, Withdrawn
AmbrisentanTemocapril may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Temocapril.Experimental, Investigational
AmifostineTemocapril may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideAmiloride may increase the hyperkalemic activities of Temocapril.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Temocapril.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Temocapril.Approved
Aminosalicylic AcidThe therapeutic efficacy of Temocapril can be decreased when used in combination with Aminosalicylic Acid.Approved
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Temocapril.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Temocapril.Approved
AmoxapineThe serum concentration of Amoxapine can be increased when it is combined with Temocapril.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Temocapril.Approved, Illicit, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Temocapril.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Temocapril.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Temocapril.Approved, Investigational
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Temocapril.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Temocapril.Approved, Investigational
AprotininAprotinin may decrease the antihypertensive activities of Temocapril.Approved, Investigational, Withdrawn
AtenololAtenolol may increase the hypotensive activities of Temocapril.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Temocapril.Approved
AvanafilAvanafil may increase the antihypertensive activities of Temocapril.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Temocapril.Withdrawn
AzathioprineThe risk or severity of anemia and severe leukopenia can be increased when Temocapril is combined with Azathioprine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Temocapril.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Temocapril.Approved, Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Temocapril.Approved, Investigational
BarnidipineTemocapril may increase the antihypertensive activities of Barnidipine.Approved
BenazeprilBenazepril may increase the hypotensive activities of Temocapril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Temocapril.Experimental
BendroflumethiazideThe risk or severity of hypotension can be increased when Bendroflumethiazide is combined with Temocapril.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Temocapril.Withdrawn
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Temocapril.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Temocapril.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Temocapril.Approved
BepridilBepridil may increase the hypotensive activities of Temocapril.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Temocapril.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Temocapril.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Temocapril.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Temocapril.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Temocapril.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Temocapril.Approved
BoceprevirThe serum concentration of Temocapril can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BosentanBosentan may increase the hypotensive activities of Temocapril.Approved, Investigational
BQ-123Temocapril may increase the hypotensive activities of BQ-123.Investigational
BretyliumBretylium may increase the hypotensive activities of Temocapril.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Temocapril.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Temocapril.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Temocapril.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Temocapril.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Temocapril.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Temocapril.Approved, Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Temocapril.Experimental
BumetanideBumetanide may increase the hypotensive activities of Temocapril.Approved
BupranololBupranolol may increase the hypotensive activities of Temocapril.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Temocapril.Approved
CadralazineCadralazine may increase the hypotensive activities of Temocapril.Experimental
CafedrineTemocapril may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinThe risk or severity of renal failure and hyperkalemia can be increased when Canagliflozin is combined with Temocapril.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Temocapril.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Temocapril.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Temocapril.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Temocapril.Approved
CarbamazepineThe metabolism of Temocapril can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe therapeutic efficacy of Temocapril can be decreased when used in combination with Carbaspirin calcium.Experimental, Investigational
CaroxazoneCaroxazone may increase the hypotensive activities of Temocapril.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Temocapril.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Temocapril.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Temocapril.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Temocapril.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Temocapril.Approved, Investigational
CeliprololCeliprolol may increase the hypotensive activities of Temocapril.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Temocapril.Approved, Investigational, Vet Approved
ChlorothiazideThe risk or severity of hypotension can be increased when Chlorothiazide is combined with Temocapril.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Temocapril.Investigational, Withdrawn
ChlorthalidoneThe risk or severity of hypotension can be increased when Chlorthalidone is combined with Temocapril.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Temocapril.Approved
CicletanineTemocapril may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilCilazapril may increase the hypotensive activities of Temocapril.Approved
CiprofloxacinThe risk or severity of ventricular arrhythmias can be increased when Temocapril is combined with Ciprofloxacin.Approved, Investigational
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Temocapril.Approved
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Temocapril.Approved, Investigational, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Temocapril.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Temocapril.Approved
CloranololTemocapril may increase the hypotensive activities of Cloranolol.Experimental
Conjugated estrogensThe serum concentration of Conjugated estrogens can be decreased when it is combined with Temocapril.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Temocapril.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Temocapril.Approved, Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Temocapril.Approved
CyclopenthiazideThe risk or severity of hypotension can be increased when Cyclopenthiazide is combined with Temocapril.Experimental
CyclophosphamideThe risk or severity of adverse effects can be increased when Temocapril is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Temocapril.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Temocapril.Approved
DapagliflozinThe risk or severity of renal failure and hyperkalemia can be increased when Dapagliflozin is combined with Temocapril.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Temocapril.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Temocapril.Approved, Investigational
DelaprilTemocapril may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Temocapril.Approved
DersalazineThe therapeutic efficacy of Temocapril can be decreased when used in combination with Dersalazine.Investigational
DeserpidineTemocapril may increase the hypotensive activities of Deserpidine.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Temocapril.Approved, Investigational
DiazoxideDiazoxide may increase the hypotensive activities of Temocapril.Approved
DibenzepinThe serum concentration of Dibenzepin can be increased when it is combined with Temocapril.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Temocapril.Approved, Vet Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Temocapril.Approved, Investigational
DiethylnorspermineDiethylnorspermine may increase the hypotensive activities of Temocapril.Investigational
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Temocapril.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Temocapril.Experimental
DiflunisalThe therapeutic efficacy of Temocapril can be decreased when used in combination with Diflunisal.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Temocapril.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Temocapril.Approved, Investigational
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Temocapril.Approved, Investigational
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Temocapril.Approved, Investigational
DorzolamideDorzolamide may increase the hypotensive activities of Temocapril.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Temocapril.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Temocapril.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Temocapril.Approved, Investigational
DrospirenoneTemocapril may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Temocapril.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Temocapril.Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Temocapril.Approved
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Temocapril.Investigational
EfonidipineTemocapril may increase the hypotensive activities of Efonidipine.Approved, Investigational
EmpagliflozinThe risk or severity of renal failure and hyperkalemia can be increased when Empagliflozin is combined with Temocapril.Approved
EnalaprilEnalapril may increase the hypotensive activities of Temocapril.Approved, Vet Approved
EnalaprilatTemocapril may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Temocapril.Experimental
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Temocapril.Approved, Investigational
EpanololTemocapril may increase the hypotensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Temocapril.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Temocapril.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Temocapril.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Temocapril.Approved
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Temocapril.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Temocapril.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Temocapril.Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Temocapril.Investigational
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Temocapril.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Temocapril.Approved, Investigational
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Temocapril.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Temocapril.Approved
Etacrynic acidEtacrynic acid may increase the hypotensive activities of Temocapril.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Temocapril.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Temocapril.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Temocapril.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Temocapril.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Temocapril.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Temocapril.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Temocapril.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Temocapril.Approved, Investigational
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Temocapril.Approved
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Temocapril.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Temocapril.Experimental
FelodipineFelodipine may increase the hypotensive activities of Temocapril.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Temocapril.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Temocapril.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Temocapril.Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Temocapril.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Temocapril.Experimental
Ferulic acidFerulic acid may increase the hypotensive activities of Temocapril.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Temocapril.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Temocapril.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Temocapril.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Temocapril.Experimental
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Temocapril.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Temocapril.Experimental
FosinoprilFosinopril may increase the hypotensive activities of Temocapril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Temocapril.Approved, Investigational, Vet Approved
FurosemideFurosemide may increase the hypotensive activities of Temocapril.Approved, Vet Approved
GarlicThe serum concentration of Temocapril can be decreased when it is combined with Garlic.Approved
GuacetisalThe therapeutic efficacy of Temocapril can be decreased when used in combination with Guacetisal.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Temocapril.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Temocapril.Approved
GuanazodineTemocapril may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Temocapril.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Temocapril.Approved, Investigational
GuanoclorTemocapril may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzTemocapril may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanTemocapril may increase the hypotensive activities of Guanoxan.Experimental
HarmalineHarmaline may increase the hypotensive activities of Temocapril.Experimental
Hemoglobin crosfumarilThe therapeutic efficacy of Temocapril can be decreased when used in combination with Hemoglobin crosfumaril.Experimental
HeparinThe risk or severity of hyperkalemia can be increased when Temocapril is combined with Heparin.Approved, Investigational
HexamethoniumTemocapril may increase the hypotensive activities of Hexamethonium.Experimental
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Temocapril.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Temocapril.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Temocapril.Experimental
HydralazineHydralazine may increase the hypotensive activities of Temocapril.Approved
HydrochlorothiazideThe risk or severity of hypotension can be increased when Hydrochlorothiazide is combined with Temocapril.Approved, Vet Approved
HydroflumethiazideThe risk or severity of hypotension can be increased when Hydroflumethiazide is combined with Temocapril.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Temocapril.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Temocapril.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Temocapril.Approved, Investigational
IloprostIloprost may increase the hypotensive activities of Temocapril.Approved, Investigational
ImidaprilTemocapril may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Temocapril.Experimental
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Temocapril.Approved
IndapamideThe risk or severity of hypotension can be increased when Indapamide is combined with Temocapril.Approved
IndenololTemocapril may increase the hypotensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Temocapril.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Temocapril.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Temocapril.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Temocapril.Withdrawn
IprindoleThe serum concentration of Iprindole can be increased when it is combined with Temocapril.Experimental
IproclozideIproclozide may increase the hypotensive activities of Temocapril.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Temocapril.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Temocapril.Approved, Investigational
IronIron can cause a decrease in the absorption of Temocapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranThe risk or severity of adverse effects can be increased when Temocapril is combined with Iron Dextran.Approved, Vet Approved
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Temocapril.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Temocapril.Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Temocapril.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Temocapril.Experimental
KetanserinKetanserin may increase the hypotensive activities of Temocapril.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Temocapril.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Temocapril.Approved
LabetalolLabetalol may increase the hypotensive activities of Temocapril.Approved
LacidipineTemocapril may increase the hypotensive activities of Lacidipine.Approved, Investigational
Lanthanum carbonateThe serum concentration of Temocapril can be decreased when it is combined with Lanthanum carbonate.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Temocapril.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Temocapril.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Temocapril.Approved, Investigational
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Temocapril.Approved
LinsidomineTemocapril may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Temocapril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Temocapril.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Temocapril.Approved
LofepramineThe serum concentration of Lofepramine can be increased when it is combined with Temocapril.Experimental
LofexidineLofexidine may increase the hypotensive activities of Temocapril.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Temocapril.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Temocapril.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Temocapril.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Temocapril.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Temocapril.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Temocapril.Approved, Investigational
MacitentanTemocapril may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Temocapril.Approved
ManidipineTemocapril may increase the hypotensive activities of Manidipine.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Temocapril.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Temocapril.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Temocapril.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Temocapril.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Temocapril.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Temocapril.Approved, Vet Approved
MesalazineThe therapeutic efficacy of Temocapril can be decreased when used in combination with Mesalazine.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Temocapril.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Temocapril.Approved, Investigational, Withdrawn
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Temocapril.Experimental
MethoserpidineTemocapril may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideThe risk or severity of hypotension can be increased when Methyclothiazide is combined with Temocapril.Approved
Methyl salicylateThe therapeutic efficacy of Temocapril can be decreased when used in combination with Methyl salicylate.Approved, Vet Approved
MethyldopaMethyldopa may increase the hypotensive activities of Temocapril.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Temocapril.Approved, Investigational
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Temocapril.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Temocapril.Approved, Investigational
MetipranololMetipranolol may increase the hypotensive activities of Temocapril.Approved
MetolazoneThe risk or severity of hypotension can be increased when Metolazone is combined with Temocapril.Approved
MetoprololMetoprolol may increase the hypotensive activities of Temocapril.Approved, Investigational
MetyrosineTemocapril may increase the hypotensive activities of Metyrosine.Approved
MibefradilMibefradil may increase the hypotensive activities of Temocapril.Investigational, Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Temocapril.Approved, Illicit
MinaprineMinaprine may increase the hypotensive activities of Temocapril.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Temocapril.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of Temocapril.Investigational
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Temocapril.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Temocapril.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Temocapril.Approved, Investigational
MoexiprilMoexipril may increase the hypotensive activities of Temocapril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Temocapril.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Temocapril.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Temocapril.Approved, Investigational
MuzolimineTemocapril may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Temocapril.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Temocapril.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Temocapril.Approved
NadololNadolol may increase the hypotensive activities of Temocapril.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Temocapril.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Temocapril.Approved
NaftopidilTemocapril may increase the hypotensive activities of Naftopidil.Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Temocapril.Approved, Vet Approved
NebivololNebivolol may increase the hypotensive activities of Temocapril.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Temocapril.Approved, Withdrawn
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Temocapril.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Temocapril.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Temocapril.Approved, Investigational
NicorandilNicorandil may increase the vasodilatory activities of Temocapril.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Temocapril.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Temocapril.Approved
NiguldipineTemocapril may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineNilvadipine may increase the hypotensive activities of Temocapril.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Temocapril.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Temocapril.Approved, Investigational
NisoldipineNisoldipine may increase the hypotensive activities of Temocapril.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Temocapril.Approved, Investigational
NitroaspirinThe therapeutic efficacy of Temocapril can be decreased when used in combination with Nitroaspirin.Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Temocapril.Approved, Investigational
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Temocapril.Approved
ObinutuzumabTemocapril may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Temocapril.Withdrawn
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Temocapril.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Temocapril.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Temocapril.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Temocapril.Investigational
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Temocapril.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Temocapril.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Temocapril.Approved
OxprenololOxprenolol may increase the hypotensive activities of Temocapril.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Temocapril.Approved, Withdrawn
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Temocapril.Approved
PargylinePargyline may increase the hypotensive activities of Temocapril.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Temocapril.Approved, Investigational
PenbutololPenbutolol may increase the hypotensive activities of Temocapril.Approved, Investigational
PentoliniumPentolinium may increase the hypotensive activities of Temocapril.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Temocapril.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Temocapril.Approved
PethidineThe risk or severity of adverse effects can be increased when Temocapril is combined with Pethidine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Temocapril.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Temocapril.Withdrawn
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Temocapril.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Temocapril.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Temocapril.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Temocapril.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Temocapril.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Temocapril.Approved
PindololPindolol may increase the hypotensive activities of Temocapril.Approved, Investigational
PiretanidePiretanide may increase the hypotensive activities of Temocapril.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Temocapril.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Temocapril.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Temocapril.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Temocapril.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Temocapril.Withdrawn
Platelet Activating FactorPlatelet Activating Factor may increase the hypotensive activities of Temocapril.Experimental
PolythiazideThe risk or severity of hypotension can be increased when Polythiazide is combined with Temocapril.Approved
PotassiumPotassium may increase the hyperkalemic activities of Temocapril.Approved, Investigational
Potassium bicarbonatePotassium bicarbonate may increase the hyperkalemic activities of Temocapril.Approved
Potassium ChloridePotassium Chloride may increase the hyperkalemic activities of Temocapril.Approved, Withdrawn
Potassium CitratePotassium Citrate may increase the hyperkalemic activities of Temocapril.Approved, Investigational, Vet Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Temocapril.Experimental, Investigational
PrazosinPrazosin may increase the hypotensive activities of Temocapril.Approved
PregabalinThe risk or severity of angioedema can be increased when Temocapril is combined with Pregabalin.Approved, Illicit, Investigational
ProcarbazineProcarbazine may increase the hypotensive activities of Temocapril.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Temocapril.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Temocapril.Approved, Investigational
PropranololPropranolol may increase the hypotensive activities of Temocapril.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Temocapril.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Temocapril.Experimental
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Temocapril.Approved
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Temocapril.Investigational
QuinaprilQuinapril may increase the hypotensive activities of Temocapril.Approved, Investigational
QuinethazoneThe risk or severity of hypotension can be increased when Quinethazone is combined with Temocapril.Approved
QuinineQuinine may increase the hypotensive activities of Temocapril.Approved
RamiprilRamipril may increase the hypotensive activities of Temocapril.Approved
RasagilineRasagiline may increase the hypotensive activities of Temocapril.Approved
RemikirenRemikiren may increase the hypotensive activities of Temocapril.Approved
RescinnamineTemocapril may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Temocapril.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Temocapril.Approved, Experimental, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Temocapril.Approved, Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Temocapril.Approved
RituximabTemocapril may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Temocapril.Approved, Investigational, Withdrawn
SacubitrilThe risk or severity of angioedema can be increased when Temocapril is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Temocapril.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Temocapril.Approved
Salicylic acidThe therapeutic efficacy of Temocapril can be decreased when used in combination with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Temocapril.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Temocapril.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Temocapril.Investigational
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Temocapril.Approved
SelegilineSelegiline may increase the hypotensive activities of Temocapril.Approved, Investigational, Vet Approved
SelexipagTemocapril may increase the hypotensive activities of Selexipag.Approved
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Temocapril.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Temocapril.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Temocapril.Investigational
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Temocapril.Approved, Investigational
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Temocapril.Approved
SirolimusThe risk or severity of angioedema can be increased when Sirolimus is combined with Temocapril.Approved, Investigational
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Temocapril.Approved, Investigational
SitaxentanTemocapril may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium aurothiomalateThe risk or severity of hypotension, nitritoid reactions, facial flushing, nausea, and vomiting can be increased when Temocapril is combined with Sodium aurothiomalate.Approved, Investigational
Sodium phosphateTemocapril may increase the nephrotoxic activities of Sodium phosphate.Approved
SpiraprilSpirapril may increase the hypotensive activities of Temocapril.Approved
SpironolactoneSpironolactone may increase the hyperkalemic activities of Temocapril.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Temocapril.Investigational
St. John's WortThe metabolism of Temocapril can be increased when combined with St. John's Wort.Approved, Investigational, Nutraceutical
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Temocapril.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Temocapril.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Temocapril.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Temocapril.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Temocapril.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Temocapril.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Temocapril.Approved, Investigational
TalinololTemocapril may increase the hypotensive activities of Talinolol.Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Temocapril.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Temocapril.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Temocapril.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Temocapril is combined with Temsirolimus.Approved
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Temocapril.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Temocapril.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Temocapril.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Temocapril.Approved
TerlipressinTerlipressin may increase the hypotensive activities of Temocapril.Approved, Investigational
TetrahydropalmatineTemocapril may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TheodrenalineTemocapril may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Temocapril.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Temocapril.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Temocapril.Approved
TiboloneTemocapril may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenTicrynafen may increase the hypotensive activities of Temocapril.Withdrawn
TimololTimolol may increase the hypotensive activities of Temocapril.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Temocapril.Investigational
TipranavirThe serum concentration of Temocapril can be decreased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of hypotension can be increased when Tizanidine is combined with Temocapril.Approved, Investigational
TolazolineTolazoline may increase the hypotensive activities of Temocapril.Approved, Vet Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Temocapril.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Temocapril.Approved
TolonidineTemocapril may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Temocapril.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Temocapril.Approved
TorasemideTorasemide may increase the hypotensive activities of Temocapril.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Temocapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Temocapril.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Temocapril.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Temocapril.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Temocapril.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Temocapril.Approved, Investigational
TriamtereneTriamterene may increase the hyperkalemic activities of Temocapril.Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Temocapril.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Temocapril.Experimental
TrichlormethiazideThe risk or severity of hypotension can be increased when Trichlormethiazide is combined with Temocapril.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Temocapril.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Temocapril.Approved, Investigational
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Temocapril.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Temocapril.Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Temocapril.Investigational
Trolamine salicylateThe therapeutic efficacy of Temocapril can be decreased when used in combination with Trolamine salicylate.Approved
UdenafilUdenafil may increase the antihypertensive activities of Temocapril.Approved, Investigational
UnoprostoneUnoprostone may increase the hypotensive activities of Temocapril.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Temocapril.Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Temocapril.Approved, Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Temocapril.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Temocapril.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Temocapril.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Temocapril.Approved
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Temocapril.Approved, Investigational
VincamineTemocapril may increase the hypotensive activities of Vincamine.Experimental
VinpocetineTemocapril may increase the hypotensive activities of Vinpocetine.Investigational
XipamideTemocapril may increase the hypotensive activities of Xipamide.Experimental
XylometazolineXylometazoline may increase the hypotensive activities of Temocapril.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Temocapril.Approved, Investigational, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Temocapril.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Temocapril.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Temocapril.Approved, Investigational, Withdrawn
ZofenoprilTemocapril may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Temocapril.Withdrawn
Food Interactions
Not Available

References

General References
  1. Tsuji A: Transporter-mediated Drug Interactions. Drug Metab Pharmacokinet. 2002;17(4):253-74. [PubMed:15618677]
  2. Furuta S, Kiyosawa K, Higuchi M, Kasahara H, Saito H, Shioya H, Oguchi H: Pharmacokinetics of temocapril, an ACE inhibitor with preferential biliary excretion, in patients with impaired liver function. Eur J Clin Pharmacol. 1993;44(4):383-5. [PubMed:8513851]
  3. Nakashima M, Yamamoto J, Shibata M, Uematsu T, Shinjo H, Akahori T, Shioya H, Sugiyama K, Kawahara Y: Pharmacokinetics of temocapril hydrochloride, a novel angiotensin converting enzyme inhibitor, in renal insufficiency. Eur J Clin Pharmacol. 1992;43(6):657-9. [PubMed:1493850]
  4. Yasunari K, Maeda K, Nakamura M, Watanabe T, Yoshikawa J, Asada A: Pharmacological and clinical studies with temocapril, an angiotensin converting enzyme inhibitor that is excreted in the bile. Cardiovasc Drug Rev. 2004 Fall;22(3):189-98. [PubMed:15492767]
  5. Clearance of Temocapril and Enalapril during Haemodialysis Treatment [Link]
External Links
Human Metabolome Database
HMDB0061720
KEGG Drug
D08566
PubChem Compound
443874
PubChem Substance
175427114
ChemSpider
391964
ChEBI
135771
ChEMBL
CHEMBL2110627
Drugs.com
Drugs.com Drug Page
Wikipedia
Temocapril
ATC Codes
C09AA14 — Temocapril
MSDS
Download (569 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)decomposes at 187Not Available
water solubility<1 mg/mLNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00342 mg/mLALOGPS
logP2.46ALOGPS
logP2.04ChemAxon
logS-5.1ALOGPS
pKa (Strongest Acidic)3.88ChemAxon
pKa (Strongest Basic)5.14ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area95.94 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity124.1 m3·mol-1ChemAxon
Polarizability49.28 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9707
Blood Brain Barrier-0.8501
Caco-2 permeable-0.6871
P-glycoprotein substrateSubstrate0.8016
P-glycoprotein inhibitor INon-inhibitor0.6373
P-glycoprotein inhibitor IINon-inhibitor0.9056
Renal organic cation transporterNon-inhibitor0.8744
CYP450 2C9 substrateNon-substrate0.6676
CYP450 2D6 substrateNon-substrate0.8686
CYP450 3A4 substrateSubstrate0.5082
CYP450 1A2 substrateNon-inhibitor0.7748
CYP450 2C9 inhibitorNon-inhibitor0.6996
CYP450 2D6 inhibitorNon-inhibitor0.8016
CYP450 2C19 inhibitorInhibitor0.5371
CYP450 3A4 inhibitorNon-inhibitor0.746
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7297
Ames testNon AMES toxic0.7962
CarcinogenicityNon-carcinogens0.8965
BiodegradationNot ready biodegradable0.9584
Rat acute toxicity2.3397 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9862
hERG inhibition (predictor II)Inhibitor0.5523
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (163 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Dipeptides
Alternative Parents
Alpha amino acid esters / Aralkylamines / Fatty acid esters / Dicarboxylic acids and derivatives / Benzene and substituted derivatives / Thiophenes / Tertiary carboxylic acid amides / Heteroaromatic compounds / Amino acids / Lactams
show 9 more
Substituents
Alpha-dipeptide / Alpha-amino acid ester / Alpha-amino acid or derivatives / Fatty acid ester / Aralkylamine / Monocyclic benzene moiety / Dicarboxylic acid or derivatives / Fatty acyl / Benzenoid / Tertiary carboxylic acid amide
show 24 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent...
Gene Name
ACE
Uniprot ID
P12821
Uniprot Name
Angiotensin-converting enzyme
Molecular Weight
149713.675 Da
References
  1. Furuta S, Kiyosawa K, Higuchi M, Kasahara H, Saito H, Shioya H, Oguchi H: Pharmacokinetics of temocapril, an ACE inhibitor with preferential biliary excretion, in patients with impaired liver function. Eur J Clin Pharmacol. 1993;44(4):383-5. [PubMed:8513851]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name
SLC15A1
Uniprot ID
P46059
Uniprot Name
Solute carrier family 15 member 1
Molecular Weight
78805.265 Da
References
  1. Tsuji A: Transporter-mediated Drug Interactions. Drug Metab Pharmacokinet. 2002;17(4):253-74. [PubMed:15618677]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. Ishizuka H, Konno K, Naganuma H, Nishimura K, Kouzuki H, Suzuki H, Stieger B, Meier PJ, Sugiyama Y: Transport of temocaprilat into rat hepatocytes: role of organic anion transporting polypeptide. J Pharmacol Exp Ther. 1998 Oct;287(1):37-42. [PubMed:9765319]

Drug created on February 19, 2013 17:04 / Updated on January 19, 2018 10:58